Travere Therapeutics
Travere Therapeutics Inc is an American biopharmaceutical company focused on identifying, developing, and commercializing therapies for rare kidney and metabolic diseases. The company commercializes Filspari (sparsentan), a first-in-class dual endothelin and angiotensin A receptor antagonist approved for reducing proteinuria in primary IgA nephropathy, alongside marketing Chenodal and Thiola for rare metabolic disorders. Main revenue drivers derive from commercial sales of Filspari, Chenodal, and Thiola specialty prescription pharmaceuticals directly to specialty pharmacies and healthcare providers. Travere Therapeutics serves nephrologists, endocrinologists, rare disease specialists, hospital centers, and patients with rare kidney conditions across North America and Europe. The company holds an innovative market position in rare nephrology and metabolic disease therapeutics. Headquartered in San Diego, California, Travere Therapeutics Inc is listed on the Nasdaq Stock Market.
6 of the funds FundTelligence covers report a position in Travere Therapeutics.
- Legal name
- Travere Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 6
Funds holding Travere Therapeutics
- Janus Henderson Horizon Biotechnology Fund — Janus Henderson · 3.87 % (largest positions only, September 2026)
- Pensum Kairos — Pensum · 1.88 % (full portfolio disclosed, June 2026)
- SEB Läkemedelsfond — SEB · 0.52 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.3 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.05 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.05 % (partially disclosed portfolio, June 2026)